Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
Efavirenz
Merck Sharp & Dohme Australia Pty Ltd
Medicine Listed (Export Only)
STOCRIN ® _Efavirenz_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about STOCRIN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking STOCRIN against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR, PHARMACIST OR TREATMENTS OFFICER AT YOUR LOCAL AIDS COUNCIL. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT STOCRIN IS USED FOR STOCRIN is used to help treat HIV (Human Immunodeficiency Virus) infection. It is used in combination with other appropriate medicines used to treat the HIV virus. Examples include protease inhibitors such as indinavir (Crixivan*) and nelfinavir (Viracept*). They also include nucleoside analogue reverse transcriptase inhibitors (NRTIs) such as zidovudine (AZT, Retrovir*) or lamivudine (3TC). STOCRIN belongs to a group of medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by interrupting the formation of new HIV particles in already infected cells. When HIV is attacked by STOCRIN, the virus is not able to reproduce normally. This helps reduce the amount of virus in the blood. Although STOCRIN helps reduce the amount of virus in the blood and thus increases the CD4 count, it has not yet been shown to improve survival or slow the progression of the disease. You may continue to develop infections or other illnesses associated with HIV disease while you are taking STOCRIN. BEFORE YOU TAKE STOCRIN _WHEN YOU MUST NOT TAKE IT_ DO NOT TAKE STOCRIN IF: • YOU HAVE AN ALLERGY TO STOCRIN OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET • THE PACKAGING IS TORN OR SHOWS SIGNS OF TAMPERING • THE EXPIRY DATE ON THE PACK HAS PASSED. If you take this medicine after the expiry date has passed, it may not work. • YOU ARE BREAST FEEDING OR PLAN TO BR Διαβάστε το πλήρες έγγραφο
WPC-MK0831-MF-032012 1 PRODUCT INFORMATION STOCRIN ® (EFAVIRENZ) TABLETS, CAPSULES AND ORAL SOLUTION NAME OF THE DRUG Efavirenz DESCRIPTION STOCRIN * is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). Efavirenz is chemically described as (S) -6- chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its empirical formula is C 14 H 9 ClF 3 NO 2 and its structural formula is: O N O Cl H F 3 C CAS Registry Number: 154598-52-4 Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (<10 g/mL). STOCRIN is available as tablets and capsules for oral administration. Each STOCRIN capsule contains 50, 100 or 200 mg and each STOCRIN tablet contains 50, 200, 300 or 600 mg of efavirenz. STOCRIN is also available as an oral solution containing 30 mg efavirenz per mL. Each capsule also contains the inactive ingredients sodium lauryl sulfate, lactose, magnesium stearate, and sodium starch glycollate. The capsule shell contains the following inactive ingredients and dyes: gelatin, sodium lauryl sulfate, titanium dioxide and/or yellow iron oxide. The capsule shells may also contain silicon dioxide. The capsules are printed with ink containing indigo carmine CI73015 and titanium dioxide. Each tablet contains the following inactive ingredients: croscarmellose sodium, cellulose - microcrystalline, sodium lauryl sulfate, hydroxypropylcellulose, lactose and magnesium stearate. The film coating contains the following inactive ingredients and dyes: ® Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., W Διαβάστε το πλήρες έγγραφο